November 8, 2024ST101, an Inhibitor of the Transcription Factor C/EBPβ, Promotes an Immune-Active Tumor Microenvironment in aWindow of Opportunity Study of Patients with GlioblastomaNovember 8, 2024ST316, a Peptide Antagonist of β-Catenin, Reprograms Immunosuppressive MyeloidCell Populations in a Phase 1 Clinical Study to Enhance Anti-Cancer Immune ResponsesJune 1, 2024Efficacy and biomarker analysis of phase 2 and window-of-opportunity cohorts of patients with glioblastoma treated with ST101, an inhibitor of the transcription factor C/EBPβApril 9, 2024ST316, a Clinical Peptide Antagonist of β-catenin, Induces Anti-Tumor Immune Responses by Multiple Mechanisms of ActionApril 8, 2024JunAP, a Peptide Antagonist of the Activator Protein 1 Transcription Factor, Demonstrates Cancer Cell Cytotoxicity and Reduced Invasion In Vitro and Tumor Regression In VivoApril 8, 2024ST101, a Clinical CEBPβ Antagonist Peptide, Promotes an Immune-Active Tumor Microenvironment by Multiple Cellular MechanismsNovember 17, 2023Neoadjuvant treatment with monotherapy ST101, a C/EBPβ antagonist, results in pathological and clinical responses in glioblastoma patients. Tissue-based analysis and clinical outcomes from a surgical window of opportunity clinical trialOctober 13, 2023Anti-tumor and Immunostimulatory Properties of ST316, a Peptide Antagonist of β-Catenin for Treatment of Cancers with Aberrant Wnt Pathway ActivityOctober 13, 2023Clinical and Biological Activity of ST101, a Peptide Antagonist of C/EBPβ, in Recurrent Glioblastoma (rGBM) Patients. Results From the rGBM Cohort of a Multi-Cohort Phase 2 StudySeptember 27, 2023Targeting the Glioblastoma Master Regulator C/EBPβ– a Pharmacokinetic and Pharmacodynamic Neoadjuvant Study of ST101April 24, 2023ST101, a peptide antagonist of novel I/O target CEBPβ, reprograms MDSC polarization and promotes an immunoactive tumor microenvironmentApril 24, 2023Immunotherapeutic potential of ST316, a peptide antagonist of β-cateninNovember 18, 2022Early signal of activity from a phase 2 study of ST101, a first-in-class peptide antagonist of CCAAT/enhancer-binding protein β (C/EBPβ), in recurrent glioblastoma (GBM)November 10, 2022ST101, a peptide antagonist of novel I/O target CEBPβ, reprograms MDSC polarization and decreases tumor-associated Tregs, suggesting an immune component to observed clinical responsesOctober 27, 2022Efficacy signals, long-term exposure and safety data from a phase 1-2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients with refractory solid tumorsJune 3, 2022Efficacy proof-of-concept from a phase 1 study of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ in patients with refractory solid tumorsApril 11, 2022Characterizing the PK/PD relationship of C/EBPβ antagonist peptide ST101 in a mouse orthotopic breast cancer modelApril 11, 2022β-catenin antagonist peptide, ST316, attenuates Wnt-dependent oncogenic activitySeptember 16, 2021Efficacy, safety, pharmacokinetic and pharmacodynamic data from phase 1 dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients with advanced and metastatic solid tumorsApril 9, 2021β-catenin antagonist peptide attenuates Wnt-dependent oncogenic activityApril 9, 2021C/EBPβ antagonist peptide, ST101, as a potential therapeutic approach in breast cancerJune 22, 2020β-catenin antagonist peptide attenuates oncogenic gene transactivation and promotes antitumor activity in breast cancer modelsJune 22, 2020C/EBPβ antagonist peptide, ST101, attenuates oncogenic gene transactivation in cancer cells to drive antitumor activityApril 1, 2019Cell penetrating peptide, ST101, disrupts ATF5 regulation of anti-apoptotic Bcl-2 family proteins, resulting in induction of cancer cell death in vitro and tumor growth inhibition/regression in vivo
